Elevation of liver enzymes within the normal limits and metabolic syndrome

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 6, 2011, Pages 373-379

  Xia, Ming Feng ^a   Yan, Hong Mei ^a   Lin, Huan Dong ^a   Bian, Hua ^a   Pan, Bai Shen ^a   Yao, Xiu Zhong ^a   Li, Ruo Kun ^a   Zeng, Meng Su ^a   Gao, Xin ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

glutamyl transpeptidase; Alanine aminotransferase; Metabolic syndrome; Non alcoholic fatty liver disease; Optimal cut off value

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER;

AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES;

EID: 79956294683     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05519.x     Document Type: Article

References (35)

1. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care 2005; 28: 2745-9.
2. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel Definition of the metabolic syndrome to Asians? Diabetes Care 2004; 27: 1182-6.
3. Mottillo S, Filion KB, Genest J et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J. Am. Coll. Cardiol. 2010; 56: 1113-32.
4. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: An update. World J. Gastroenterol. 2008; 14: 185-92.
5. Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed? Dig. Dis. 2005; 23: 72-82.
6. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
7. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.
8. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N. Engl. J. Med. 2000; 342: 1266-71.
9. Nakanishi N, Suzuki K, Tatara K. Serum γ-glutamyltransferase and risk of metabolic syndrome and Type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004; 27: 1427-32.
10. Oh SY, Cho YK, Kang MS et al. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism 2006; 55: 1604-9.
11. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig. Dis. 2010; 28: 155-61.
12. Kasapoglu B, Turkay C, Bayram Y, Koca C. Role of GGT in diagnosis of metabolic syndrome: A clinic-based cross-sectional survey. Indian J. Med. Res. 2010; 132: 56-61.
13. Steinvil A, Shapira I, Ben-Bassat OK et al. The association of higher levels of within-normal-limits liver enzymes and the prevalence of the metabolic syndrome. Cardiovasc. Diabetol. 2010; 15: 30.
14. Prati D, Taioli E, Zanella A et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med. 2002; 137: 1-9.
15. Farrell GC, Chitturi S, Lau GK, Sollano JD, Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: Executive summary. J. Gastroenterol. Hepatol. 2007; 22: 775-7.
16. Liu M, Gao X, Rao SX, Wu L, Zeng MS. Measurement of intrahepatic triglyceride stores by 1H magnetic resonance spectroscopy: Study with rat models and in patients. Zhonghua Yi Xue Za Zhi 2008; 88: 531-3.
17. Szczepaniak LS, Nurenberg P, Leonard D et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab. 2005; 288: 462-8.
18. Bian H, Yan H, Zeng M et al. Increased liver fat content and unfavorable glucose profiles in subjects without diabetes. Diabetes Technol. Ther. 2011; 13: 149-55.
19. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: A new worldwide definition. A consensus statement from the International Diabetes Federation. Diabet. Med. 2006; 23: 469-80.
20. Perkins NJ, Schisterman EF. The inconsistency of 'optimal' cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am. J. Epidemiol. 2006; 163: 670-5.
21. Marchesini G, Avagnina S, Barantani EG et al. Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J. Endocrinol. Invest. 2005; 28: 333-9.
22. Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: Results from the third National Health Nutrition Survey (NHANES III) Am. J. Med. Sci. 2005; 329: 111-16.
23. Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: The British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009; 32: 741-50.
24. Schindhelm RK, Dekker JM, Nijpels G et al. Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn Study. Atherosclerosis 2007; 191: 391-6.
25. Lee DS, Evans JC, Robins SJ et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: The Framingham Heart Study. Arterioscler. Thromb. Vasc. Biol. 2007; 27: 127-33.
26. Hsieh MH, Ho CK, Hou NJ et al. Abnormal liver function test results are related to metabolic syndrome and BMI in Taiwanese adults without chronic hepatitis B or C. Int. J. Obes. 2009; 33: 1309-17.
27. Kang YH, Min HG, Kim IJ, Kim YK, Son SM. Comparison of alanine aminotransferase, white blood cell count, and uric acid in their association with metabolic syndrome: A study of Korean adults. Endocr. J. 2008; 55: 1093-102.
28. Oda E, Kawai R, Watanabe K, Sukumaran V. Prevalence of metabolic syndrome increases with the increase in blood levels of gamma glutamyltransferase and alanine aminotransferase in Japanese men and women. Intern. Med. 2009; 48: 1343-50.
29. Kirovski G, Schacherer D, Wobser H et al. Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease in a hospital cohort and its association with anthropometric, biochemical and sonographic characteristics. Int. J. Clin. Exp. Med. 2010; 3: 202-10.
30. Yki-Järvinen H. Liver fat in the pathogenesis of insulin resistance and Type 2 diabetes. Dig. Dis. 2010; 28: 203-9.
31. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 679-89.
32. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin. Liver Dis. 2001; 21: 17-26.
33. Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 2005; 42: 1460-1.
34. Schwimmer JB, Dunn W, Norman GJ et al. SAFETY study: Alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010; 138: 1357-64.
35. Needleman L, Kurtz AB, Rifkin MD, Cooper HS, Pasto ME, Goldberg BB. Sonography of diffuse benign liver disease. Accuracy of pattern recognition and grading. AJR Am. J. Roentgenol. 1986; 146: 1011-15.